These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24692356)

  • 21. Repolarization gradients and arrhythmogenicity in the murine heart.
    Killeen MJ; Sabir IN
    J Physiol; 2007 Sep; 583(Pt 2):419-20. PubMed ID: 17627980
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Dtsch Med Wochenschr; 2012 Aug; 137(33):1654-8. PubMed ID: 22875694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short QT syndrome. Update on a recent entity.
    Maury P; Extramiana F; Sbragia P; Giustetto C; Schimpf R; Duparc A; Wolpert C; Denjoy I; Delay M; Borggrefe M; Gaita F
    Arch Cardiovasc Dis; 2008; 101(11-12):779-86. PubMed ID: 19059573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postnatal development has a marked effect on ventricular repolarization in mice.
    Grandy SA; Trépanier-Boulay V; Fiset C
    Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2168-77. PubMed ID: 17675571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic management of arrhythmias.
    Ganjehei L; Massumi A; Nazeri A; Razavi M
    Tex Heart Inst J; 2011; 38(4):344-9. PubMed ID: 21841856
    [No Abstract]   [Full Text] [Related]  

  • 26. Heritable arrhythmias associated with abnormal function of cardiac potassium channels.
    Crotti L; Odening KE; Sanguinetti MC
    Cardiovasc Res; 2020 Jul; 116(9):1542-1556. PubMed ID: 32227190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of potassium currents in cardiac arrhythmias.
    Ravens U; Cerbai E
    Europace; 2008 Oct; 10(10):1133-7. PubMed ID: 18653669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial fibrillation in the goat induces changes in monophasic action potential and mRNA expression of ion channels involved in repolarization.
    van der Velden HMW ; van der Zee L; Wijffels MC; van Leuven C; Dorland R; Vos MA; Jongsma HJ; Allessie MA
    J Cardiovasc Electrophysiol; 2000 Nov; 11(11):1262-9. PubMed ID: 11083247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockers of the slowly delayed rectifier potassium IKs channel: potential antiarrhythmic agents.
    Gerlach U
    Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):243-52. PubMed ID: 15326915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac electrophysiological effects of nitric oxide.
    Tamargo J; Caballero R; Gómez R; Delpón E
    Cardiovasc Res; 2010 Sep; 87(4):593-600. PubMed ID: 20587506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use-dependent modulation of myocardial conduction by a new class of HERG agonists: deal breaker or cherry on top?
    Akar FG
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):930-2. PubMed ID: 20367661
    [No Abstract]   [Full Text] [Related]  

  • 33. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
    McEwen DP; Martens JR
    Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
    Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studying cardiac arrhythmias in the mouse--a reasonable model for probing mechanisms?
    Nerbonne JM
    Trends Cardiovasc Med; 2004 Apr; 14(3):83-93. PubMed ID: 15121155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
    Singh BN
    J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels.
    Iskit AB; Erkent U; Ertunc M; Guc MO; Ilhan M; Onur R
    Vascul Pharmacol; 2007 Feb; 46(2):129-36. PubMed ID: 17064967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac mitochondria and arrhythmias.
    Brown DA; O'Rourke B
    Cardiovasc Res; 2010 Nov; 88(2):241-9. PubMed ID: 20621924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization.
    Rivard K; Paradis P; Nemer M; Fiset C
    Cardiovasc Res; 2008 Apr; 78(1):53-62. PubMed ID: 18245065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Slow delayed rectifier potassium current (IKs) and the repolarization reserve.
    Jost N; Papp JG; Varró A
    Ann Noninvasive Electrocardiol; 2007 Jan; 12(1):64-78. PubMed ID: 17286653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.